Next, we evaluated the CD8 T cell repertoire that can be raised using the V-peptide variant and if these T cells cross-react to the wild-type LRPAP121–30 peptide, which is naturally presented by TAP-deficient immune-escaped cancer cells. This evidence concerns the gene CD8A and cancer.